NorthStar secures up to $185 million to scale Actinium-225 production

1 October 2026

NorthStar Medical Technologies, the US radiopharma company, has secured a multi-year growth capital facility of up to $185 million from Hercules Capital (NYSE: HTGC), the specialty finance company, to expand its isotope production and radiopharmaceutical manufacturing capacity.

The financing, which includes $100 million upfront, will accelerate investment in NorthStar's vertically integrated campus in Bseloit, Wisconsin, which combines co-located isotope production with a contract development and manufacturing organization (CDMO). 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical